These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26004580)

  • 1. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
    Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
    Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
    Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism.
    Palanski BA; Khosla C
    Biochemistry; 2018 Jun; 57(24):3359-3363. PubMed ID: 29570977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase as a therapeutic target for celiac disease.
    Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
    Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinnamoyl inhibitors of tissue transglutaminase.
    Pardin C; Pelletier JN; Lubell WD; Keillor JW
    J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of transglutaminase 2 in celiac disease pathogenesis.
    Klöck C; Diraimondo TR; Khosla C
    Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation and inhibition of transglutaminase 2 in mice.
    Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
    PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
    Klöck C; Herrera Z; Albertelli M; Khosla C
    J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
    Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
    Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
    Plugis NM; Palanski BA; Weng CH; Albertelli M; Khosla C
    J Biol Chem; 2017 Feb; 292(5):2000-2008. PubMed ID: 28003361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
    Dafik L; Khosla C
    Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival.
    Vyas FS; Hargreaves AJ; Bonner PL; Boocock DJ; Coveney C; Dickenson JM
    Biochem Pharmacol; 2016 May; 107():41-58. PubMed ID: 27005940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
    van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
    Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β
    Vyas FS; Nelson CP; Freeman F; Boocock DJ; Hargreaves AJ; Dickenson JM
    Eur J Pharmacol; 2017 Oct; 813():105-121. PubMed ID: 28754379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
    Badarau E; Collighan RJ; Griffin M
    Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
    Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
    Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
    Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y
    J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.